MedTrace Logo

Plasma Dipeptidyl-peptidase-4 Activities With No-reflow and Bleeding

NCT02849691 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 747

Last updated 2016-07-29

No results posted yet for this study

Summary

Dipeptidyl-peptidase-4 (DPP4) is an important regulator of incretins and inflammation, and participates in the pathophysiological process of acute myocardial infarction (AMI). However clinical data of DPP4a in AMI patients is sparse. This study was to investigate the role of plasma DPP4 activity (DPP4a) in patients with ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI). This was a analysis of consecutive patients conducted at a tertiary referral center from January 2014 to October 2015. The investigators included 747 STEMI-patients, treated with PCI from January 2013 to October 2015. Blood samples were collected immediately at admission. The patients were divided into four groups according to DPP4a quartile.

Conditions

  • Dipeptidyl-peptidase-4
  • STEMI
  • PCI
  • No-reflow
  • Bleeding

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02849691 on ClinicalTrials.gov